Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan/Aventis Terminate Zagam Deal; Mylan Clears Books Of Pending Suits

Executive Summary

Mylan and Aventis are ending the Zagam marketing deal under a settlement of claims arising from supply problems with the antibiotic

You may also be interested in...



BuSpar Antitrust Settlement Is Two-Times Sales During Extended Patent Life

Bristol-Myers Squibb's proposed $535 mil. payment to settle BuSpar antitrust litigation amounts to more than twice the sales of the anxiety drug during the four months of extended exclusivity for the product that prompted the suits

Mylan Zagam

Mylan "has indicated that they are presently marketing the antibiotic Zagam and it remains a part of their Bertek branded product line," the company stated Feb. 16. The generics manufacturer previously indicated that it was discontinuing Zagam (1"The Pink Sheet" Feb. 5, p. 29). Mylan said it wrote down $3.6 mil. of the Zagam (sparfloxacin) product license in its Jan. 30 third quarter report because of "supply issues," and that it "continues to work to try to resolve the issues surrounding Zagam"

Mylan Must Give FTC 30-Day Notice Before Any Exclusive Bulk Agreement

Mylan has to give the Federal Trade Commission 30-day advance notice for any exclusive agreements dealing with active pharmaceutical ingredients under a Nov. 29 consent decree.

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel